Ontology highlight
ABSTRACT: Background
Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing disease with challenging management. To find novel effective therapies, better preclinical models are needed for the screening of anti-fibrotic compounds. Activated fibroblasts drive fibrogenesis and are the main cells responsible for the accumulation of extracellular matrix (ECM). Here, a prolonged Scar-in-a-Jar assay was combined with clinically validated biochemical markers of ECM synthesis to evaluate ECM synthesis over time. To validate the model as a drug screening tool for novel anti-fibrotic compounds, two approved compounds for IPF, nintedanib and pirfenidone, and a compound in development, omipalisib, were tested.Methods
Primary human lung fibroblasts from healthy donors were cultured for 12 d
SUBMITTER: Ronnow SR
PROVIDER: S-EPMC7203825 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature